Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL

著者: Barr, Paul M., Saylors, Gene B., Spurgeon, Stephen E., Cheson, Bruce D., Greenwald, Daniel R., O’Brien, Susan M., Liem, Andre K. D., Mclntyre, Rosemary E., Joshi, Adarsh, Abella-Dominicis, Esteban, Hawkins, Michael J., Reddy, Anita, Di Paolo, Julie, Lee, Hank, He, Joyce, Hu, Jing, Dreiling, Lyndah K., Friedberg, Jonathan W.
出版年 Blood (2016)

Idelalisib or Placebo in Combination with Bendamustine and Rituximab in Patients with Relapsed/Refractory CLL - Interim Results of a Phase 3 Randomized, Double-blind Placebo-Contro...

著者: Zelenetz, Andrew D., Barrientos, Jacqueline C., Brown, Jennifer R., Coiffier, Bertrand, Delgado, Julio, Egyed, Miklós, Ghia, Paolo, Illés, Árpád, Jurczak, Wojciech, Marlton, Paula, Montillo, Marco, Morschhauser, Franck, Pristupa, Alexander S., Robak, Tadeusz, Sharman, Jeff P., Simpson, David, Smolej, Lukáš, Tausch, Eugen, Adewoye, Adeboye H., Dreiling, Lyndah K., Kim, Yeonhee, Stilgenbauer, Stephan, Hillmen, Peter
出版年 Lancet Oncol (2017)

Risk Model for Overall Survival in Relapsed or Refractory Chronic Lymphocytic Leukaemia in the Era of Targeted Therapies

著者: Soumerai, Jacob D., Ni, Ai, Darif, Mohamed, Londhe, Anil, Xing, Guan, Mun, Yong, Kay, Neil E., Shanafelt, Tait D., Rabe, Kari G., Byrd, John C., Chanan-Khan, Asher A., Furman, Richard R., Hillmen, Peter, Jones, Jeffrey, Seymour, John F., Sharman, Jeffrey P., Ferrante, Lucille, Mobasher, Mehrdad, Stark, Thomas, Reddy, Vijay, Dreiling, Lyndah K., Bhargava, Pankaj, Howes, Angela, James, Danelle F., Zelenetz, Andrew D.
出版年 Lancet Haematol (2019)